

Remarks

A one month extension of time is enclosed.

Amendments have been made by the applicants to claims 1 to 19. Claim 20 has been cancelled. New claim 25 has been added.

In the specification, the word "novel" has been removed from the Abstract, as requested by the Examiner.

Claims 2-19 have been amended to refer to the 'photoresist composition of claim 1'. Claim 1 has also been amended to further define structure 2, in that the group $W(CF_3)_2OH$ is capped, such that $W(CF_3)_2OH$ is further reacted with a capping group to protect the hydroxyl group and make it insoluble in an aqueous² alkaline solution. Support for such an amendment is present in the specification on page 7, lines 25-27. No new matter has been added to the claim.

The applicants do not fully comprehend the Examiner's comment in paragraph 9. A telephone call was placed to the Examiner on June 2, but the voice mail stated that the Examiner would not be back till June 9. However, since the response to the Office Action is due on June 6, with 1 month extension of time, the Examiner is requested to explain the full meaning of paragraph 9, either in writing or by contacting the Agent by telephone.

The exposure wavelength in claim 13 refers to any wavelength that is used to expose the photoresist and can range from 100nm to 300nm. Typical wavelengths are 193nm and 157nm.

*Support
for
entire
range?*

The Examiner has rejected claims 1-3, 6-14, 16-17, and 20-24 under 35 USC 102(e) as being anticipated by Fryd et al.

The Examiner also has rejected claims 4 and 15 under 35 USC 103(a) as being unpatentable over Fryd as applied to claims 1-3, 6-14, 16-17, and 20-24, and further rejected claims 18-19 under 35 USC 103(a) as being unpatentable over Fryd as applied to claims 1-3, 6-14, 16-17, and 20-24, and further in view of Choi.

The Examiner has objected to claim 5 as being dependent upon a rejected claim, but would be allowable if rewritten in independent form and including all the limitations of the base claim and any intervening claims.

The applicants believe that with the amendment to claim 1, such that the fluoroalcohol group claimed by Fryd is excluded, claim 1 is now allowable.

The Commissioner is hereby authorized to charge deposit account 03-2060 \$ 0 for the additional claim(s). The Commissioner is also authorized to credit any overpayment or charge any fee deficiency to Deposit Account No. 03-2060.

In conclusion and in view of the above, it is respectfully submitted to the Examiner that the present invention with the amended claims is now placed in a condition of allowance.

If any points remain at issue which can best be resolved by way of a telephonic or personal interview, the Examiner is kindly requested to contact the undersigned agent at the number listed below.

Respectfully submitted,



Sangya Jain
Reg. No. 38,504
Clariant Corporation
70 Meister Avenue
Somerville, NJ 08876
Telephone: (908) 429-3536